Changeflow GovPing Pharma & Drug Safety Antisense Oligonucleic Acid Patent - Osaka Univ...
Routine Notice Added Final

Antisense Oligonucleic Acid Patent - Osaka University EP3587576A1

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office granted patent EP3587576A1 to Osaka University covering antisense oligonucleic acid compositions. The patent names inventors Obika, Satoshi; Waki, Reiko; Inoue, Takao; Yoshida, Tokuyuki; Morihiro, Kunihiko; Kasahara, Yuya; and Mikami, Atsushi. The patent is classified under IPC codes C12N 15/113, A61K 31/7115, A61K 31/712, and A61P 43/00, indicating pharmaceutical and therapeutic applications. Protection extends to designated contracting states including Germany, France, the United Kingdom, and other EU member states.

What changed

The European Patent Office published EP3587576A1, a patent application for antisense oligonucleic acid technology filed by Osaka University. The patent covers compositions and methods related to therapeutic oligonucleotides, with IPC classifications indicating pharmaceutical applications including A61K 31/7115 and A61K 31/712.

For pharmaceutical and biotechnology companies developing oligonucleotide-based therapeutics, this patent establishes intellectual property protection in European markets. Entities should review this patent when designing clinical programs or seeking European market authorization for similar antisense technologies to assess potential licensing requirements or freedom-to-operate considerations.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ANTISENSE OLIGONUCLEIC ACID

Publication EP3587576A1 Kind: A1 Apr 08, 2026

Applicants

Osaka University

Inventors

OBIKA, Satoshi, WAKI, Reiko, INOUE, Takao, YOSHIDA, Tokuyuki, MORIHIRO, Kunihiko, KASAHARA, Yuya, MIKAMI, Atsushi

IPC Classifications

C12N 15/113 20100101AFI20201127BHEP A61K 31/7115 20060101ALI20201127BHEP A61K 31/712 20060101ALI20201127BHEP A61P 43/00 20060101ALI20201127BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3587576A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Patent application Biotechnology Therapeutic development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!